Live Breaking News & Updates on Including Phlebitis

Stay updated with breaking news from Including phlebitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novel Supportive Approach in Cancer Care Helps Protect Patients' Bone Marrow from Chemotherapy Damage

Novel Supportive Approach in Cancer Care Helps Protect Patients' Bone Marrow from Chemotherapy Damage
oncologynurseadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oncologynurseadvisor.com Daily Mail and Mail on Sunday newspapers.

Jared Weiss , Tammy Allred , Dorothy Turner , Lineberger Comprehensive Cancer Center , Therapeutics Inc , International Journal Of Cancer , Comprehensive Cancer , Site Reactions , Including Phlebitis , Sodium Chloride Injection , Dextrose Injection , Basu Roy United Kingdom ,

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Jared Weiss , University Of North Carolina Chapel Hill , Exchange Commission , Drug Administration On , Lineberger Comprehensive Cancer Center , Therapeutics Inc , Pivotal Program Evaluated The Effects Of Administering , Research Triangle Park , Division Of Oncology , Investor Relations Corporate Communications , Program Evaluated , Including Hematologic Adverse Events , Laboratory Values , Supportive Care Interventions , Significant Decreases , Most Measures , Clinical Lung Cancer , Drug Administration , Patient Reported Outcomes , Extensive Stage Small Cell Lung Cancer , Pooled Results , Three Phase , Placebo Controlled Studies , Associate Professor , North Carolina Chapel Hill ,

FDA Approves G1 Therapeutics' COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression Nasdaq:GTHX

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
February 12, 2021 19:41 ET
| Source:
G1 Therapeutics
G1 Therapeutics
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with
extensive-stage small cell lung cancer
being treated with chemotherapy -
- Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions -
- G1 will host conference call Tuesday, February 16, 2021 at 8:00 a.m. ET -
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administr ....

Puerto Rico , United States , Jeffrey Crawford , Christine Rogers , Bonniej Addario , Jack Bailey , Duke Cancer Institute , Boehringer Ingelheim , Drug Administration , Exchange Commission , Therapeutics Inc , Foundation For Lung Cancer , Corporate Communications , Research Triangle Park , Geller Professor For Research , Department Of Medicine , Geller Professor , Duke Cancer , Chief Executive Officer , Breakthrough Therapy Designation , Conference Call , Co Promotion Agreement , Small Cell , Site Reactions , Including Phlebitis , Sodium Chloride Injection ,